147 related articles for article (PubMed ID: 36202686)
1. Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy.
Mertens LS; Meijer RP; Alfred Witjes J
Eur Urol; 2023 Feb; 83(2):95-96. PubMed ID: 36202686
[TBL] [Abstract][Full Text] [Related]
2. A rare presentation of primary synchronous renal tract tumours on (18F)- fluorodeoxyglucose positron emission tomography- computed tomography.
Ahmad W; Gill SM; Hassan A
J Pak Med Assoc; 2020 May; 70(5):942-943. PubMed ID: 32400761
[TBL] [Abstract][Full Text] [Related]
3. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.
Goodfellow H; Viney Z; Hughes P; Rankin S; Rottenberg G; Hughes S; Evison F; Dasgupta P; O'Brien T; Khan MS
BJU Int; 2014 Sep; 114(3):389-95. PubMed ID: 24341486
[TBL] [Abstract][Full Text] [Related]
4. [(18)F]Fluorodeoxyglucose - positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy.
Kollberg P; Almquist H; Bläckberg M; Cronberg C; Garpered S; Gudjonsson S; Kleist J; Lyttkens K; Patschan O; Liedberg F
Scand J Urol; 2015; 49(4):296-301. PubMed ID: 25623843
[TBL] [Abstract][Full Text] [Related]
5. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study.
Hitier-Berthault M; Ansquer C; Branchereau J; Renaudin K; Bodere F; Bouchot O; Rigaud J
Int J Urol; 2013 Aug; 20(8):788-96. PubMed ID: 23279605
[TBL] [Abstract][Full Text] [Related]
6. Editorial comment on: FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
Sherif A
Eur Urol; 2010 Apr; 57(4):647. PubMed ID: 19477582
[No Abstract] [Full Text] [Related]
7. Staging
Voskuilen CS; van Gennep EJ; Einerhand SMH; Vegt E; Donswijk ML; Bruining A; van der Poel HG; Horenblas S; Hendricksen K; van Rhijn BWG; Mertens LS
Eur Urol Oncol; 2022 Jun; 5(3):366-369. PubMed ID: 33583752
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
[TBL] [Abstract][Full Text] [Related]
9. Patient-Friendly Summary of the ACR Appropriateness Criteria: Pretreatment Staging of Muscle-Invasive Bladder Cancer.
Rybicki F; Glanc P
J Am Coll Radiol; 2019 Jun; 16(6):e25. PubMed ID: 31171142
[No Abstract] [Full Text] [Related]
10. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
Mertens LS; Mir MC; Scott AM; Lee ST; Fioole-Bruining A; Vegt E; Vogel WV; Manecksha R; Bolton D; Davis ID; Horenblas S; van Rhijn BW; Lawrentschuk N
Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
[TBL] [Abstract][Full Text] [Related]
11. 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer.
Einerhand SMH; van Gennep EJ; Mertens LS; Hendricksen K; Donswijk ML; van der Poel HG; van Rhijn BWG
Curr Opin Urol; 2020 Sep; 30(5):654-664. PubMed ID: 32701719
[TBL] [Abstract][Full Text] [Related]
12. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 11C-choline with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study.
Golan S; Sopov V; Baniel J; Groshar D
J Urol; 2011 Aug; 186(2):436-41. PubMed ID: 21679983
[TBL] [Abstract][Full Text] [Related]
14. PET/CT in Bladder Cancer: An Update.
Bouchelouche K
Semin Nucl Med; 2022 Jul; 52(4):475-485. PubMed ID: 34996595
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma.
Lodde M; Lacombe L; Friede J; Morin F; Saourine A; Fradet Y
BJU Int; 2010 Sep; 106(5):658-63. PubMed ID: 20151968
[TBL] [Abstract][Full Text] [Related]
16. Is [F-18]-fluorodeoxyglucose FDG-PET/CT better than ct alone for the preoperative lymph node staging of muscle invasive bladder cancer?
Uttam M; Pravin N; Anish B; Nandita K; Arup M
Int Braz J Urol; 2016; 42(2):234-41. PubMed ID: 27256176
[TBL] [Abstract][Full Text] [Related]
17. PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
Bouchelouche K; Choyke PL
PET Clin; 2015 Jul; 10(3):361-74. PubMed ID: 26099672
[TBL] [Abstract][Full Text] [Related]
18. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
19. Integrated analysis of
Girard A; Rouanne M; Taconet S; Radulescu C; Neuzillet Y; Girma A; Beaufrere A; Lebret T; Le Stanc E; Grellier JF
Eur Radiol; 2019 Aug; 29(8):4286-4293. PubMed ID: 30666449
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
